ArticleFrontiers in pharmacology2023
Bridging the new drug access gap between China and the United States and its related policies.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Development Timelines of Innovative Drugs in China: A 15-Year Cross-Sectional Analysis of Characteristics and Influencing Factors.Clinical and translational science · 2026Article
- International approval of Chinese pharmaceuticals: a USA-anchored analysis with comparative insights from Europe and other markets.EClinicalMedicine · 2026Article
- Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.BMC health services research · 2026Article
- Thailand's Emerging Role in the Cell and Gene Therapy Revolution: A Review of Progress and Potential.Clinical and translational science · 2026Review
- Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges.Clinical pharmacology and therapeutics · 2026Article
- Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a review.Frontiers in oncology · 2026Review
- Reconceiving orphan drug market exclusivity as a conditional public-law entitlement: a sustainable regulatory governance model with comparative lessons for China.Frontiers in medicine · 2026Article
- Research on the innovation of medical expenses protection mechanism for rare disease patients in China.Frontiers in public health · 2026Article
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Approval Disparities for New Drugs in the US and Japan.JAMA network open · 2025Article
- Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies.Global health research and policy · 2025Article
- Promoting the development and approval of new traditional Chinese medicines in China: a pooled analysis of data from 2013 to 2024.Frontiers in medicine · 2025Article
- Drug lag and associated factors of orphan drugs approved by the U.S. in China.Frontiers in pharmacology · 2025Article
- Disparities in the access to immune checkpoint inhibitors approved in the United States, the European Union and mainland China: a serial cross-sectional study.BMJ public health · 2025Article
- Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China.Heliyon · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.